REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
REGENERON PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$782.04−8.70 (-1.10%)
Close on Oct 19, 2026
- Market cap
- $82.90B
- P/E (TTM)
- 19.3
- Dividend yield
- –
REGENERON PHARMACEUTICALS, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration revenue | $7.33B | $6.06B | $5.50B | $4.91B | $3.67B | $1.19B | – | – | – | – | 51.1% | +21.0% |
| Net product sales | $6.31B | $7.63B | $7.08B | $6.89B | $12.12B | $5.57B | $4.83B | $4.11B | $3.72B | $3.34B | 44.0% | -17.3% |
| Libtayo | $1.45B | $1.22B | $863.10M | $447.50M | $306.30M | – | – | – | – | – | 10.1% | +19.3% |
| Other revenue | $702.60M | $515.00M | $536.10M | $365.10M | $281.20M | $557.00M | $174.00M | – | – | – | 4.9% | +36.4% |
| Other products | $10.10M | $0 | $0 | – | – | – | – | – | – | – | 0.1% | – |
| ARCALYST | – | – | – | – | – | – | – | – | $16.55M | $15.31M | – | – |
| EYLEA | – | – | – | – | – | – | – | – | $3.70B | $3.32B | – | – |
| Sanofi collaboration revenue | – | – | – | $2.86B | $1.90B | $1.19B | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Regeneron Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.